Inside informationEnglish
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 20/10/2025, 08:30
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 113877_20251020